Related Experiment Video
Updated: Oct 19, 2025
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Panagiotis Theofilis1, Aikaterini Vordoni1, Maria Koukoulaki1
1Department of Nephrology, General Hospital of Nikaia-Piraeus, Athens, Greece.
Insights
Managing dyslipidemia in chronic kidney disease (CKD) is crucial for reducing cardiovascular risks. Current statin therapy effectiveness is limited in end-stage renal disease, prompting research into novel treatments.
Area of Science:
- Nephrology
- Cardiology
- Metabolic Disorders
Background:
- Chronic kidney disease (CKD) is a growing health concern associated with high rates of cardiovascular complications.
- Dyslipidemia is a key modifiable risk factor that requires careful management in CKD patients.
Purpose of the Study:
- To review the pathophysiology of altered lipid profiles in CKD.
- To outline current management strategies for dyslipidemia in CKD based on recent guidelines.
- To discuss emerging therapeutic approaches for dyslipidemia in CKD.
Main Methods:
- Literature review of pathophysiologic evidence and clinical guidelines.
- Analysis of current and emerging therapeutic strategies for dyslipidemia in CKD.
Main Results:
- Renal impairment significantly alters lipid metabolism, cholesterol structure, and promotes oxidative stress.
- Statins are foundational for managing dyslipidemia and cardiovascular risk in CKD, but their role in end-stage renal disease on dialysis is debated.
- Novel therapies targeting hypertriglyceridemia, PCSK9, and Lp(a) are under investigation, with potential insights from gut microbiome research.
Conclusions:
- CKD profoundly impacts lipid profiles, necessitating tailored management strategies.
- While statins are standard, their limitations in advanced CKD highlight the need for innovative treatments.
- Emerging therapies and understanding the gut microbiome offer promising avenues for improving cardiovascular outcomes in CKD patients.
Background:
Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia.
Summary:
In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelines. Moreover, we present the current progress regarding the emerging therapeutic strategies. Key Messages: The presence of renal impairment leads to alterations in cholesterol structure, metabolism, and reverse transport paired with increased oxidative stress. Statins remain the cornerstone of dyslipidemia management in patients with kidney dysfunction who are at risk for cardiovascular events. However, their efficacy is debatable in end-stage renal disease under renal replacement therapy. Therefore, novel treatment approaches aiming at hypertriglyceridemia, proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) are under rigorous investigation while the research of gut microbiome might provide additional mechanistic and therapeutic insight.
More Related Videos
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management
01:20Acute Kidney Injury V: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention